

Table SI. Fold change values treatment of cell lines with cetuximab and fractionated radiotherapy.

	Ctrl	Cetux	RT	Cetux+ RT
11B pERK1/2	1.00	1.12	1.11	1.05
11B PD-L1	1.00	0.89	1.21	1.02
22B pERK1/2	1.00	0.75	1.02	0.94
22B PD-L1	1.00	1.13	0.98	1.01
14c pERK1/2	1.00	0.63	1.02	0.64
14c PD-L1	1.00	0.22	1.20	0.29

Mock treated controls were set '1'. p, phosphorylated; PD-L1, programmed cell death ligand-1; Ctrl, control; Cetux, cetuximab; RT, radiotherapy.

Table SII. Fold change values treatment of cell lines with cisplatin and fractionated radiotherapy.

	Ctrl	Cis1	Cis5	RT	RT+Cis1	RT+Cis5
11B pERK1/2	1	1.3	1.2	1.1	1.5	2.9
11B PD-L1	1	3.6	3.3	2	5.4	17.3
22B pERK1/2	1	0.8	0.6	2	1.3	3.4
22B PD-L1	1	3.6	13.2	2.8	4.3	12.8
14C pERK1/2	1	0.9	1.7	0.8	1.2	2.3
14C PD-L1	1	1.5	18.7	2.2	5.6	33.4

Mock treated controls were set '1'.p, phosphorylated; PD-L1,programmedcelldeath ligand-1; Ctrl, control; Cis, cisplatin; RT, radiotherapy.

Table SIII. Ratio of densitometric values of pERK1/2/tERK1/2.

	Ctrl	Cetux	RT	Cetux + RT
UM-SCC-11B	0.332	0.511	0.327	0.524
UM-SCC-14C	0.284	0.066	0.107	0.026
UM-SCC-22B	0.247	0.244	0.299	0.184

p, phosphorylated; t, total; Ctrl, control; Cetux, cetuximab; RT, radiotherapy.

Table SIV. Ratio of densitometric values of pERK1/2/tERK1/2.

	Ctrl	RT	Cis1	Cis5	Cis1 + RT	Cis5 + RT
UM-SCC-11B	0.321	0.427	0.581	0.685	0.373	0.155
UM-SCC-14C	0.302	0.280	0.350	0.391	0.361	0.237
UM-SCC-22B	0.231	0.493	0.551	0.283	0.358	0.576

p, phosphorylated; t, total; Ctrl, control; Cis, cisplatin; RT, radiotherapy.